Last reviewed · How we verify
Bacterial Lysate
At a glance
| Generic name | Bacterial Lysate |
|---|---|
| Also known as | Broncho Vaxom |
| Sponsor | Fondazione Policlinico Universitario Campus Bio-Medico |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- OM-85 in Paediatric Recurrent Respiratory Tract Infections With Wheezing Lower Respiratory Illness (PHASE4)
- A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing (PHASE2)
- Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness (PHASE2)
- Bacterial Lysate In Preventing Asthma (PHASE2)
- OM 85 to Prevent Respiratory Infections in Older At Risk Patients (PHASE4)
- PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study (PHASE2)
- OM 85 to Prevent Respiratory Infections in Older At Risk Patients (PHASE4)
- Protecting Preterm Infants From Respiratory Tract Infections and Wheeze by Using Bacterial Lysates. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bacterial Lysate CI brief — competitive landscape report
- Bacterial Lysate updates RSS · CI watch RSS
- Fondazione Policlinico Universitario Campus Bio-Medico portfolio CI